ENDLOS-TURBO PUT - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 04:04:54 2024-07-01 EDT | ||
| 3.83 EUR | +7.28% |
|
| Current month | -28.17% | ||
| 1 month | -36.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 3.83 | +7.28% |
| 24-06-28 | 3.57 | +6.25% |
| 24-06-27 | 3.36 | -2.89% |
| 24-06-26 | 3.46 | -0.86% |
| 24-06-25 | 3.49 | +7.38% |
Delayed Quote Deutsche Boerse AG
Last update July 01, 2024 at 04:04 am
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | DZ BANK |
| WKN | DJ2LN2 |
| ISIN | DE000DJ2LN24 |
| Date issued | 2023-09-21 |
| Strike | 507 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 13.42 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.38 € |
|---|---|
| Lowest since issue | 2.22 € |
| Spread | 0.2 € |
| Spread % | 5.03% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
